Business Description
PharmaEngine Inc
NAICS : 325412
SIC : 2834
ISIN : TW0004162003
Description
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 412.46 | |||||
| Equity-to-Asset | 0.98 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | 1843.9 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 99.08 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.6 | |||||
| 3-Year EBITDA Growth Rate | -22.8 | |||||
| 3-Year EPS without NRI Growth Rate | -22.7 | |||||
| 3-Year FCF Growth Rate | 59.5 | |||||
| 3-Year Book Growth Rate | -0.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.02 | |||||
| 9-Day RSI | 57.17 | |||||
| 14-Day RSI | 51.44 | |||||
| 6-1 Month Momentum % | -1.67 | |||||
| 12-1 Month Momentum % | -10.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 53.67 | |||||
| Quick Ratio | 53.55 | |||||
| Cash Ratio | 49.76 | |||||
| Days Inventory | 170.25 | |||||
| Days Sales Outstanding | 35.67 | |||||
| Days Payable | 251.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.63 | |||||
| Dividend Payout Ratio | 0.58 | |||||
| 3-Year Dividend Growth Rate | 58.7 | |||||
| Forward Dividend Yield % | 1.63 | |||||
| 5-Year Yield-on-Cost % | 3.15 | |||||
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 1.78 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.46 | |||||
| Operating Margin % | 47.21 | |||||
| Net Margin % | 44.49 | |||||
| FCF Margin % | 49.23 | |||||
| ROE % | 9.49 | |||||
| ROA % | 9.17 | |||||
| ROIC % | 149.36 | |||||
| ROC (Joel Greenblatt) % | 408.13 | |||||
| ROCE % | 11.55 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 35.86 | |||||
| Forward PE Ratio | 30.63 | |||||
| PE Ratio without NRI | 35.86 | |||||
| Shiller PE Ratio | 29.7 | |||||
| Price-to-Owner-Earnings | 32.43 | |||||
| PEG Ratio | 1.16 | |||||
| PS Ratio | 15.97 | |||||
| PB Ratio | 3.33 | |||||
| Price-to-Tangible-Book | 3.32 | |||||
| Price-to-Free-Cash-Flow | 32.41 | |||||
| Price-to-Operating-Cash-Flow | 32.31 | |||||
| EV-to-EBIT | 21.03 | |||||
| EV-to-EBITDA | 20.59 | |||||
| EV-to-Revenue | 11.4 | |||||
| EV-to-FCF | 21.41 | |||||
| Price-to-Projected-FCF | 1.71 | |||||
| Price-to-Median-PS-Value | 0.65 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.43 | |||||
| Price-to-Graham-Number | 2.29 | |||||
| Price-to-Net-Current-Asset-Value | 3.34 | |||||
| Price-to-Net-Cash | 3.61 | |||||
| Earnings Yield (Greenblatt) % | 4.77 | |||||
| FCF Yield % | 3.12 | |||||
| Forward Rate of Return (Yacktman) % | 22.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
PharmaEngine Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 831.921 | ||
| EPS (TTM) (NT$) | 2.58 | ||
| Beta | 0.58 | ||
| Volatility % | 37.07 | ||
| 14-Day RSI | 51.44 | ||
| 14-Day ATR (NT$) | 2.61463 | ||
| 20-Day SMA (NT$) | 90.54 | ||
| 12-1 Month Momentum % | -10.38 | ||
| 52-Week Range (NT$) | 74.8 - 115 | ||
| Shares Outstanding (Mil) | 143.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaEngine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaEngine Inc Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaEngine Inc Frequently Asked Questions
What is PharmaEngine Inc(ROCO:4162)'s stock price today?
The current price of ROCO:4162 is NT$92.00. The 52 week high of ROCO:4162 is NT$115.00 and 52 week low is NT$74.80.
When is next earnings date of PharmaEngine Inc(ROCO:4162)?
The next earnings date of PharmaEngine Inc(ROCO:4162) is .
Does PharmaEngine Inc(ROCO:4162) pay dividends? If so, how much?
The Dividend Yield % of PharmaEngine Inc(ROCO:4162) is 1.63% (As of Today), Highest Dividend Payout Ratio of PharmaEngine Inc(ROCO:4162) was 3.45. The lowest was 0.12. And the median was 0.86. The Forward Dividend Yield % of PharmaEngine Inc(ROCO:4162) is 1.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers